Page 135 - 《中国药房》2025年17期

（9）：1965-1982. [21] MCGOWAN B M，BRUUN J M，CAPEHORN M，et al.
[ 7 ] HOLST J J. The physiology of glucagon-like peptide 1[J]. Efficacy and safety of once-weekly semaglutide 2.4 mg
Physiol Rev，2007，87（4）：1409-1439. versus placebo in people with obesity and prediabetes
[ 8 ] 卢伟涛，何家汝，陈文瑛 . 基于 FAERS 数据库的司美格 （STEP 10） ：a randomised，double-blind，placebo-
鲁肽药品不良事件信号挖掘[J]. 中国药房，2022，33 controlled，multicentre phase 3 trial[J]. Lancet Diabetes
（15）：1865-1869，1875. Endocrinol，2024，12（9）：631-642.
[ 9 ] 叶小珍，邵加庆. 司美格鲁肽的临床应用研究进展[J].中 [22] KADOWAKI T，ISENDAHL J，KHALID U，et al. Sema‐
华糖尿病杂志，2022，14（1）：1-8. glutide once a week in adults with overweight or obesity，
[10] LUQUET S，PHILLIPS C T，PALMITER R D. NPY/ with or without type 2 diabetes in an East Asian popula‐
AgRP neurons are not essential for feeding responses to tion （STEP 6）：a randomised，double-blind，double-
glucoprivation[J]. Peptides，2007，28（2）：214-225. dummy，placebo-controlled，phase 3a trial[J]. Lancet Dia‐
[11] COWLEY M A，SMART J L，RUBINSTEIN M，et al. betes Endocrinol，2022，10（3）：193-206.
Leptin activates anorexigenic POMC neurons through a [23] MU Y M，BAO X L，ELIASCHEWITZ F G，et al. Effi‐
neural network in the arcuate nucleus[J]. Nature，2001， cacy and safety of once weekly semaglutide 2.4 mg for
411（6836）：480-484. weight management in a predominantly East Asian popula‐
[12] LIU J Y，JING C Q，GUO Y，et al. The central signaling tion with overweight or obesity （STEP 7）：a double-blind，
pathways related to metabolism-regulating hormones of multicentre，randomised controlled trial[J]. Lancet Diabe‐
the gut-brain axis：a review[J]. J Transl Med，2025，23 tes Endocrinol，2024，12（3）：184-195.
（1）：648. [24] RUBINO D，ABRAHAMSSON N，DAVIES M，et al. Ef‐
[13] CHAO A M，TRONIERI J S，AMARO A，et al. Semaglu‐ fect of continued weekly subcutaneous semaglutide vs pla‐
tide for the treatment of obesity[J]. Trends Cardiovasc cebo on weight loss maintenance in adults with over‐
Med，2023，33（3）：159-166. weight or obesity：the STEP 4 randomized clinical trial[J].
[14] LEXCHIN J，MINTZES B. Semaglutide：a new drug for JAMA，2021，325（14）：1414-1425.
the treatment of obesity[J]. Drug Ther Bull，2023，61（12）： [25] KNOP F K，ARODA V R，DO VALE R D，et al. Oral
182-188. semaglutide 50 mg taken once per day in adults with over‐
[15] WILDING J P H，BATTERHAM R L，CALANNA S， weight or obesity （OASIS 1）：a randomised，double-
et al. Once-weekly semaglutide in adults with overweight blind，placebo-controlled，phase 3 trial[J]. Lancet，2023，
or obesity[J]. N Engl J Med，2021，384（11）：989-1002. 402（10403）：705-719.
[16] WADDEN T A，BAILEY T S，BILLINGS L K，et al. Ef‐ [26] ClinicalTrials.gov research team. A research study on how
fect of subcutaneous semaglutide vs placebo as an adjunct well semaglutide works in adolescents with overweight or
to intensive behavioral therapy on body weight in adults obesity （NCT04102189）[EB/OL]. [2025-06-13]. https：//
with overweight or obesity：the STEP 3 randomized clini‐ clinicaltrials.gov/ct2/show/NCT04102189.
cal trial[J]. JAMA，2021，325（14）：1403-1413. [27] ClinicalTrials.gov research group. Research study to inves‐
[17] GARVEY W T，BATTERHAM R L，BHATTA M，et al. tigate how well semaglutide works in people living with
Two-year effects of semaglutide in adults with overweight heart failure and obesity （STEP-HFpEF，NCT04788511）
or obesity：the STEP 5 trial[J]. Nat Med，2022，28（10）： [EB/OL]. [2025-06-13]. https：//clinicaltrials.gov/ct2/show/
2083-2091. NCT04788511.
[18] DAVIES M，FÆRCH L，JEPPESEN O K，et al. Semaglu‐ [28] CONTI M，PONTIGGIA L，VERGANI M，et al. Comparing
tide 2.4 mg once a week in adults with overweight or obe‐ medication persistence with oral and subcutaneous sema‐
sity，and type 2 diabetes （STEP 2）：a randomised，double- glutide in a real-world setting[J]. Acta Diabetol，2025，62
blind，double-dummy，placebo-controlled，phase 3 trial[J]. （7）：1065-1072.
Lancet，2021，397（10278）：971-984. [29] SARAVANAN P，BELL H，BRAAE U C，et al. PIONEER
[19] RUBINO D M，GREENWAY F L，KHALID U，et al. Ef‐ REAL UK：a multi-centre，prospective，real-world study
fect of weekly subcutaneous semaglutide vs daily liraglu‐ of once-daily oral semaglutide use in adults with type 2
tide on body weight in adults with overweight or obesity diabetes[J]. Adv Ther，2024，41（11）：4266-4281.
without diabetes：the STEP 8 randomized clinical trial[J]. [30] WANG W Q，BAIN S C，BIAN F，et al. Efficacy and
JAMA，2022，327（2）：138-150. safety of oral semaglutide monotherapy vs placebo in a
[20] BLIDDAL H，BAYS H，CZERNICHOW S，et al. Once- predominantly Chinese population with type 2 diabetes
weekly semaglutide in persons with obesity and knee （PIONEER 11）：a double-blind，phase Ⅲ a，randomised
osteoarthritis[J]. N Engl J Med，2024，391（17）：1573- trial[J]. Diabetologia，2024，67（9）：1783-1799.
1583. [31] JI L N，AGESEN R M，BAIN S C，et al. Efficacy and

中国药房 2025年第36卷第17期 China Pharmacy 2025 Vol. 36 No. 17 · 2209 ·